(Reuters) - Gilead Sciences and the U.S. government have settled a billion-dollar patent dispute over Gilead's HIV prevention ...

Biotech dealmaking is back — but smaller and more intimate. Deals disclosed in the early days of the new year indicate that ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

After years of sparring, the Biden administration and Gilead Sciences have settled a contentious lawsuit over patents for a ...

Gilead Sciences (NASDAQ:GILD) has reportedly settled a patent lawsuit with the federal government over its HIV drugs Truvada ...

U.S. President Joe Biden said on Wednesday (January 15) that Israel and Hamas have reached a ceasefire and hostage deal that ...

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $91 which represents a slight increase of $1.06 or 1.18% from the prior close of $89.94. The stock opened at $90.59 and touched ...

Two moon landers, one from Japan's ispace and another from U.S. space firm Firefly, began their journeys into space on Wednesday (January 15) with SpaceX's unusual double moonshot launch, underscoring ...

Current treatments for dermatomyositis include various immunosuppressants and immunosuppressive agents, including ...

From groundbreaking immunotherapies to advanced targeted treatments, oncology is set to make historic strides in the year ahead.

Extended-course nirmatrelvir/ritonavir yields a meaningful reduction in symptoms for some patients with long COVID, but not all benefits persist.

Research presented at SABCS 2024 provided new insights that may influence the management of early and advanced breast cancer.